Suven Pharmaceuticals Limited
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- ₹509
- Today's High:
- ₹522.4
- Open Price:
- ₹517.6
- 52W Low:
- ₹375
- 52W High:
- ₹534.55
- Prev. Close:
- ₹518.85
- Volume:
- 35472
Company Statistics
- Market Cap.:
- ₹129.24 billion
- Book Value:
- 68.164
- Revenue TTM:
- ₹13.49 billion
- Operating Margin TTM:
- 39.57%
- Gross Profit TTM:
- ₹7.55 billion
- Profit Margin:
- 31.45%
- Return on Assets TTM:
- 17.09%
- Return on Equity TTM:
- 25.21%
Company Profile
Suven Pharmaceuticals Limited had its IPO on under the ticker symbol SUVENPHAR.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Suven Pharmaceuticals Limited has a staff strength of 0 employees.
Stock update
Shares of Suven Pharmaceuticals Limited opened at ₹517.6 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of ₹509 - ₹522.4, and closed at ₹513.55.
This is a -1.02% slip from the previous day's closing price.
A total volume of 35,472 shares were traded at the close of the day’s session.
In the last one week, shares of Suven Pharmaceuticals Limited have increased by +1.17%.
Suven Pharmaceuticals Limited's Key Ratios
Suven Pharmaceuticals Limited has a market cap of ₹129.24 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.
In the last 12-months Suven Pharmaceuticals Limited’s revenue was ₹13.49 billion with a gross profit of ₹7.55 billion and an EBITDA of ₹5.82 billion. The EBITDA ratio measures Suven Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Suven Pharmaceuticals Limited’s operating margin was 39.57% while its return on assets stood at 17.09% with a return of equity of 25.21%.
In Q2, Suven Pharmaceuticals Limited’s quarterly earnings growth was a positive 12.3% while revenue growth was a positive 2.6%.
Suven Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 30.4742
- PEG
Its diluted EPS in the last 12-months stands at ₹16.66 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Suven Pharmaceuticals Limited’s profitability.
Suven Pharmaceuticals Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.
Suven Pharmaceuticals Limited stock pays annual dividends of ₹0 per share, indicating a yield of 0.59% and a payout ratio of 84.96%.
Balance sheet and cash flow metrics
- Total Assets
- ₹19.66 billion
- Total Liabilities
- ₹1.59 billion
- Operating Cash Flow
- ₹0
- Capital Expenditure
- ₹0
- Dividend Payout Ratio
- 84.96%
Suven Pharmaceuticals Limited ended 2025 with ₹19.66 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹19.66 billion while shareholder equity stood at ₹17.35 billion.
Suven Pharmaceuticals Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹1.59 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹648.03 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹45.64 million.
Suven Pharmaceuticals Limited’s total current assets stands at ₹10.11 billion while long-term investments were ₹0 and short-term investments were ₹4.22 billion. Its net receivables were ₹1.11 billion compared to accounts payable of ₹651.64 million and inventory worth ₹3.13 billion.
In 2025, Suven Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, Suven Pharmaceuticals Limited paid ₹0.85 in dividends in 2025.
Other key metrics
- Current Trading Price
- ₹513.55
- 52-Week High
- ₹534.55
- 52-Week Low
- ₹375
- Analyst Target Price
- ₹
Suven Pharmaceuticals Limited stock is currently trading at ₹513.55 per share. It touched a 52-week high of ₹534.55 and a 52-week low of ₹534.55. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹499.78 and 200-day moving average was ₹483.84 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 6603.4% of the company’s stock are held by insiders while 1622.2% are held by institutions.
Frequently Asked Questions About Suven Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.